放疗联合全程新辅助治疗用于既往放疗后复发直肠癌的多中心前瞻性观察研究(RETRY)
RETRY是一项由意大利AIRO胃肠道肿瘤组设计的多中心前瞻性观察研究,计划3年内入组88例既往接受过盆腔放疗的局部复发直肠癌成人患者,主要目标是评估3年局部控制率,次要结局包括生存、生活质量及手术病例的R0切除率。新辅助方案为常规分割放疗最低40 Gy同步氟嘧啶类联合或不联合奥沙利铂化疗,或SBRT 35–40 Gy分5次;不可手术者接受碳离子放疗40–60 Gy RBE、每日3–4.8 Gy RBE。
要点
- 研究对象为既往接受过盆腔放疗的局部复发直肠癌成人患者,计划3年入组88例。
- 主要终点为3年局部控制率,次要终点包括生存、生活质量及手术病例R0切除率。
- 新辅助常规分割放疗最低40 Gy同步氟嘧啶类联合或不联合奥沙利铂化疗;SBRT为35–40 Gy分5次。
核心结论
- RETRY试验旨在探讨放疗联合化疗并在可行时加入手术的综合方案能否改善局部复发直肠癌患者的生存和生活质量。
研究设计与样本
- 由意大利擅长直肠癌及局部复发直肠癌管理的中心专家合作设计,在AIRO胃肠道肿瘤组内开展的多中心前瞻性观察研究。
- 入组对象为既往接受过盆腔放疗、符合特定标准并隶属于参与研究的意大利中心的成人局部复发直肠癌患者,计划3年内共入组88例。
- 转诊碳离子放疗需满足特定标准。
主要发现
- 主要目标为确定3年局部控制率。
- 次要结局包括评估生存、生活质量以及手术病例的R0切除率。
关键数值与推荐
- 新辅助常规分割放疗最低剂量40 Gy,同步氟嘧啶类联合或不联合奥沙利铂化疗。
- SBRT剂量为35–40 Gy分5次,基于临床判断决定。
- 上述方案中质子和光子治疗均将被评估。
- 不可手术病例接受碳离子放疗,剂量40–60 Gy RBE,每日分次剂量3–4.8 Gy RBE。
- 若评估为可手术则考虑手术。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Local recurrence of rectal cancer (LRRC) previously treated with radiotherapy is associated with a poor prognosis. Historically, the integration of radiotherapy (RT) with surgery has improved the likelihood of complete resections (R0) and, consequently, enhanced survival. Unfortunately, many LRRC cases are not amenable to surgical intervention. The inclusion of chemotherapy (CHT) alongside advanced RT techniques including proton and carbon ion RT (CIRT) and stereotactic body radiation therapy (SBRT), has generated new treatment options. Therefore, there is a need for improved stratification of LRRC patients to enhance treatment outcomes. The RETRY is an integrated trial with the primary aim to explore if combining CHT with RT in all available modalities can enhance local control (LC) in LRRC patients, consequently improving survival. METHODS: Experts from Italian centers specializing in rectal cancer and LRRC management collaborated to design a prospective multicenter observational study within the AIRO group for gastrointestinal malignancies. Eligible participants are adult LRRC patients who previously had pelvic RT, meet specific criteria, and are affiliated with the participating Italian centers. Specific criteria must be met for CIRT referral. A total of 88 patients will be enrolled over three years. The primary objective is to determine the 3-year LC rate. Secondary outcomes include assessing survival, quality of life, and R0 resection rates in surgery cases. A minimum dose of 40 Gy, conventional fractionation with concomitant fluoropyrimidine-with/without oxaliplatin-based CHT (CRT) is prescribed in neoadjuvant setting. Alternatively, the dose will vary from 35 to 40 Gy in 5 fractions based on clinical judgment, by SBRT. Both proton and photon therapies will be evaluated in these approaches. Surgery will be considered if deemed operable. In inoperable cases, CIRT with a dose of 40-60 Gy relative biological effectiveness (RBE) will be administered with a daily dose fraction ranging between 3 and 4.8 Gy RBE. DISCUSSION: The RETRY trial aims to investigate the combined effects of RT and CHT and when feasible the addition of surgery, to determine whether this comprehensive approach can result in improved survival and quality of life for LRRC patients. Trial registration number ClinicalTrials.gov (No. NCT05984576).
引用
- Gambacorta MA, Romano A, Caravatta L, et al. Radiotherapy & total neoadjuvant therapy for recurrent rectal cancer in previously irradiated patients, (RETRY): a multicenter prospective observational study. Radiat Oncol. 2024. PMID: 39695675. doi:10.1186/s13014-024-02555-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。